Pharma BD Deal Intelligence

Endo International plc / Grupo Farmaceutico Somar SAPI de CV

2014 · Acquisition/Merger · $270M · Complete

Announcement Sentiment

Positive

Endo agreed to acquire privately held Mexico City-based specialty pharma Somar for cash, with reported value of approximately US$270M. The deal extended Endo's international branded footprint into Latin America, with 60+ products in the launch pipeline. Closed July 24, 2014.

Did it work? Outcome assessment

Strategic verdict

Failed to Achieve

Financial impact

Impaired/Written Down

Assessment window: 5yr post-close.

Key facts

Announced Apr 29, 2014
Closed Jul 24, 2014
Deal value $270M
Deal type Acquisition/Merger
Therapeutic area Latin American specialty branded pharmaceuticals
Indications Latin American specialty branded pharmaceuticals
Key assets Mexican specialty pharma portfolio (60+ products in pipeline)
Mechanism Mixed mechanism (specialty branded portfolio)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals